vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and First Savings Financial Group, Inc. (FSFG). Click either name above to swap in a different company.

First Savings Financial Group, Inc. is the larger business by last-quarter revenue ($1.5M vs $1.4M, roughly 1.1× FATE THERAPEUTICS INC). On growth, First Savings Financial Group, Inc. posted the faster year-over-year revenue change (-0.7% vs -26.4%). First Savings Financial Group, Inc. produced more free cash flow last quarter ($78.3M vs $-112.0M). Over the past eight quarters, FATE THERAPEUTICS INC's revenue compounded faster (-15.7% CAGR vs -70.2%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

FATE vs FSFG — Head-to-Head

Bigger by revenue
FSFG
FSFG
1.1× larger
FSFG
$1.5M
$1.4M
FATE
Growing faster (revenue YoY)
FSFG
FSFG
+25.7% gap
FSFG
-0.7%
-26.4%
FATE
More free cash flow
FSFG
FSFG
$190.3M more FCF
FSFG
$78.3M
$-112.0M
FATE
Faster 2-yr revenue CAGR
FATE
FATE
Annualised
FATE
-15.7%
-70.2%
FSFG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FATE
FATE
FSFG
FSFG
Revenue
$1.4M
$1.5M
Net Profit
$5.3M
Gross Margin
Operating Margin
Net Margin
350.2%
Revenue YoY
-26.4%
-0.7%
Net Profit YoY
37.9%
43.5%
EPS (diluted)
$0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
FSFG
FSFG
Q4 25
$1.4M
Q3 25
$1.7M
$1.5M
Q2 25
$1.9M
$1.4M
Q1 25
$1.6M
$1.5M
Q4 24
$1.9M
$1.5M
Q3 24
$3.1M
$1.5M
Q2 24
$6.8M
$1.4M
Q1 24
$1.9M
$18.0M
Net Profit
FATE
FATE
FSFG
FSFG
Q4 25
Q3 25
$-32.3M
$5.3M
Q2 25
$-34.1M
$6.2M
Q1 25
$-37.6M
$5.5M
Q4 24
$6.2M
Q3 24
$-47.7M
$3.7M
Q2 24
$-38.4M
$4.1M
Q1 24
$-48.0M
$4.9M
Operating Margin
FATE
FATE
FSFG
FSFG
Q4 25
Q3 25
-1995.1%
Q2 25
-1938.5%
Q1 25
-2534.1%
Q4 24
Q3 24
-1703.9%
Q2 24
-665.7%
Q1 24
-2652.9%
32.1%
Net Margin
FATE
FATE
FSFG
FSFG
Q4 25
Q3 25
-1852.4%
350.2%
Q2 25
-1786.6%
441.1%
Q1 25
-2309.5%
377.2%
Q4 24
424.0%
Q3 24
-1551.0%
242.4%
Q2 24
-567.4%
295.8%
Q1 24
-2493.7%
27.3%
EPS (diluted)
FATE
FATE
FSFG
FSFG
Q4 25
Q3 25
$-0.27
$0.76
Q2 25
$-0.29
$0.88
Q1 25
$-0.32
$0.79
Q4 24
$0.89
Q3 24
$-0.40
$0.53
Q2 24
$-0.33
$0.60
Q1 24
$-0.47
$0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
FSFG
FSFG
Cash + ST InvestmentsLiquidity on hand
$203.7M
$31.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$193.5M
Total Assets
$318.9M
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
FSFG
FSFG
Q4 25
$203.7M
Q3 25
$215.4M
$31.9M
Q2 25
$222.8M
$52.1M
Q1 25
$240.4M
$28.7M
Q4 24
$279.1M
$76.2M
Q3 24
$296.9M
$52.1M
Q2 24
$304.9M
$42.4M
Q1 24
$121.3M
$63.0M
Stockholders' Equity
FATE
FATE
FSFG
FSFG
Q4 25
$207.2M
Q3 25
$234.1M
$193.5M
Q2 25
$261.4M
$183.8M
Q1 25
$288.4M
$179.2M
Q4 24
$318.7M
$176.0M
Q3 24
$362.3M
$177.1M
Q2 24
$397.0M
$168.0M
Q1 24
$426.1M
$165.1M
Total Assets
FATE
FATE
FSFG
FSFG
Q4 25
$318.9M
Q3 25
$343.7M
$2.4B
Q2 25
$371.6M
$2.4B
Q1 25
$398.7M
$2.4B
Q4 24
$440.7M
$2.4B
Q3 24
$495.0M
$2.5B
Q2 24
$528.8M
$2.4B
Q1 24
$569.9M
$2.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
FSFG
FSFG
Operating Cash FlowLast quarter
$-106.1M
$79.1M
Free Cash FlowOCF − Capex
$-112.0M
$78.3M
FCF MarginFCF / Revenue
-8183.9%
5199.5%
Capex IntensityCapex / Revenue
434.8%
58.4%
Cash ConversionOCF / Net Profit
15.01×
TTM Free Cash FlowTrailing 4 quarters
$-199.6M
$51.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
FSFG
FSFG
Q4 25
$-106.1M
Q3 25
$-24.4M
$79.1M
Q2 25
$-24.6M
$6.5M
Q1 25
$-33.8M
$-32.8M
Q4 24
$-122.9M
$177.0K
Q3 24
$-29.4M
$91.2M
Q2 24
$-32.3M
$-655.0K
Q1 24
$-33.4M
$7.7M
Free Cash Flow
FATE
FATE
FSFG
FSFG
Q4 25
$-112.0M
Q3 25
$-26.6M
$78.3M
Q2 25
$-25.9M
$6.5M
Q1 25
$-35.0M
$-32.9M
Q4 24
$-123.6M
$-347.0K
Q3 24
$-29.9M
$90.5M
Q2 24
$-32.4M
$-702.0K
Q1 24
$-33.4M
$7.7M
FCF Margin
FATE
FATE
FSFG
FSFG
Q4 25
-8183.9%
Q3 25
-1526.5%
5199.5%
Q2 25
-1360.7%
462.7%
Q1 25
-2148.9%
-2258.8%
Q4 24
-6645.4%
-23.6%
Q3 24
-973.1%
5974.9%
Q2 24
-477.8%
-51.0%
Q1 24
-1736.9%
42.6%
Capex Intensity
FATE
FATE
FSFG
FSFG
Q4 25
434.8%
Q3 25
126.5%
58.4%
Q2 25
71.4%
0.5%
Q1 25
73.4%
8.7%
Q4 24
39.2%
35.7%
Q3 24
16.1%
45.1%
Q2 24
0.8%
3.4%
Q1 24
4.5%
0.0%
Cash Conversion
FATE
FATE
FSFG
FSFG
Q4 25
Q3 25
15.01×
Q2 25
1.05×
Q1 25
-5.97×
Q4 24
0.03×
Q3 24
24.84×
Q2 24
-0.16×
Q1 24
1.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons